<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; CMC</title>
	<atom:link href="http://www.stockbloghub.com/tag/cmc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(CMC) Company News for December 20, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/12/20/cmc-company-news-for-december-20-2011-corporate-summary/88962</link>
		<comments>http://www.stockbloghub.com/2011/12/20/cmc-company-news-for-december-20-2011-corporate-summary/88962#comments</comments>
		<pubDate>Tue, 20 Dec 2011 18:11:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Steel & Iron]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[Red Hat Inc.]]></category>
		<category><![CDATA[RHT]]></category>
		<category><![CDATA[SCHN]]></category>
		<category><![CDATA[Schnitzer Steel Industries Inc]]></category>
		<category><![CDATA[WINN]]></category>
		<category><![CDATA[Winn-Dixie Stores Inc.]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88962</guid>
		<description><![CDATA[•    In a deal worth $560 million, Winn-Dixie Stores Inc. (NASDAQ:WINN) will be sold to supermarket operator Bi-Lo LLC. Following the development, shares of Winn-Dixie soared 70.1% •    A company spokeswoman told Reuters that Procter &#38; Gamble Co. (NYSE:PG) has stopped full-time hiring for this fiscal year •    Schnitzer Steel Industries Inc. (NASDAQ:SCHN) said that weak environment for recycled metals on a global basis will take a toll on its first quarter fiscal 2012 earnings, dragging them lower. The company now expects earnings per share to come in between $0.18 and $0.25 •    Shares of Commercial Metals Company (NYSE:CMC) slid 1.4% after the company declined investor Carl Icahn’s $1.7 billion acquisition bid •    According to British newspaper The Independent, Exxon Mobil Corporation (NYSE:XOM) has offered to acquire U.K.&#8217;s Gulf Keystone ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/20/cmc-company-news-for-december-20-2011-corporate-summary/88962/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Loss Narrows on Lower Costs</title>
		<link>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027</link>
		<comments>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027#comments</comments>
		<pubDate>Thu, 28 Jul 2011 04:23:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80027</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 21 cents per share in the second quarter of 2011, a penny wider than the Zacks Consensus Estimate but well below the year-ago loss of 28 cents. Despite a decline in revenues, year-over-year loss declined due to lower expenses. Second quarter revenues declined 3.8% to $158.1 million. Revenues, however, exceeded the Zacks Consensus Estimate of $156 million. Quarterly Details Total revenues for the quarter declined mainly due to lower net product sales. Quarterly revenues consisted of $154.8 million in product sales (down 4.8%) and $3.3 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Product revenues comprised $129 million in sales of Byetta (exenatide) and $25.8 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GE) General Electric Aviation Gets Orders Worth $27 Billion</title>
		<link>http://www.stockbloghub.com/2011/06/29/ge-general-electric-aviation-gets-orders-worth-27-billion/77919</link>
		<comments>http://www.stockbloghub.com/2011/06/29/ge-general-electric-aviation-gets-orders-worth-27-billion/77919#comments</comments>
		<pubDate>Wed, 29 Jun 2011 20:30:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Conglomerates]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77919</guid>
		<description><![CDATA[GE Aviation, a part of General Electric (GE) and Nexcelle have signed an agreement whereby Nexcelle’s nacelle system (a streamlined enclosure on an aircraft that provides shelter to the crew, cargo and the engine) will be included in the GE Passport 20 jet engine. This agreement was signed by the companies at the Paris Air Show. As per the agreement, Nexcelle will develop, produce and deliver nacelles and thrust reversers for GE Aviation’s Passport 20 jet engine’s integrated propulsion system. This new propulsion system will be used on GE’s new Bombardier Global 7000 and 8000 business jet aircraft. Nexcelle is a leading supplier of engine nacelles, thrust reversers and aerostructures. Based in Cincinati, Ohio, the company offers expertise in the design, development, production and support of integrated propulsion systems for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/ge-general-electric-aviation-gets-orders-worth-27-billion/77919/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AKS) Stock Market News for April 20, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/04/20/aks-stock-market-news-for-april-20-2011-market-news/71975</link>
		<comments>http://www.stockbloghub.com/2011/04/20/aks-stock-market-news-for-april-20-2011-market-news/71975#comments</comments>
		<pubDate>Wed, 20 Apr 2011 21:36:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Steel & Iron]]></category>
		<category><![CDATA[AK Steel Holding Corporation]]></category>
		<category><![CDATA[AKS]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Nucor Corporation]]></category>
		<category><![CDATA[NUE]]></category>
		<category><![CDATA[Steel Dynamics Inc.]]></category>
		<category><![CDATA[STLD]]></category>
		<category><![CDATA[United States Steel Corporation]]></category>
		<category><![CDATA[Us Bancorp]]></category>
		<category><![CDATA[USB]]></category>
		<category><![CDATA[VMW]]></category>
		<category><![CDATA[VMware Inc.]]></category>
		<category><![CDATA[X]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>
		<category><![CDATA[ZION]]></category>
		<category><![CDATA[Zions BanCorporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71975</guid>
		<description><![CDATA[On Tuesday, markets ended with modest gains as an earnings-driven trading day witnessed positive results and sentiments were boosted by strong results from bellwether stocks. Earnings reports of healthcare stocks helped push the markets higher aided by steel stocks. Tech majors such as IBM and Intel also posted encouraging results surpassing estimates. Encouraging data reflecting strengthening new-home construction added to the cheer. The indices rebounded on Tuesday and the Dow Jones Industrial Average gained 0.5% to close at 12,266.75. The Standard &#38; Poor 500 Index gained 0.6% and ended at 1,312.62, just 2.50 points lower than its 50-day moving average. The Nasdaq closed at 2,744.97 after gaining 0.4%. The fear-gauge CBOE Volatility Index (VIX) dropped below 16. On the New York Stock Exchange, for every two advancing shares, one stock ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/20/aks-stock-market-news-for-april-20-2011-market-news/71975/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Reports Earnings Loss In-Line with Estimates</title>
		<link>http://www.stockbloghub.com/2011/04/20/amln-amylin-pharmaceuticals-reports-earnings-loss-in-line-with-estimates/71977</link>
		<comments>http://www.stockbloghub.com/2011/04/20/amln-amylin-pharmaceuticals-reports-earnings-loss-in-line-with-estimates/71977#comments</comments>
		<pubDate>Wed, 20 Apr 2011 21:35:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71977</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 24 cents per share in the first quarter of 2011, in line with the Zacks Consensus Estimate and 3 cents below the year-ago loss of 27 cents. Despite a decline in revenues, year-over-year loss declined due to lower expenses. First quarter revenues declined 12.3% to $152.7 million. Revenues also missed the Zacks Consensus Estimate of $155 million. Quarterly Details Total revenues for the quarter declined 12.3% mainly due to lower net product sales. Quarterly revenues consisted of $150.8 million in product sales (down 12.5%) and $1.9 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Product revenues comprised $128 million in sales of Byetta (exenatide) and $22.8 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/20/amln-amylin-pharmaceuticals-reports-earnings-loss-in-line-with-estimates/71977/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Analyst Reports Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/03/29/amln-amylin-pharmaceuticals-analyst-reports-neutral-on-shares/68498</link>
		<comments>http://www.stockbloghub.com/2011/03/29/amln-amylin-pharmaceuticals-analyst-reports-neutral-on-shares/68498#comments</comments>
		<pubDate>Tue, 29 Mar 2011 14:41:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68498</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Amylin Pharmaceuticals, Inc. (AMLN). The company reported a net loss of $0.94 per share in 2010, narrower than the Zacks Consensus Estimate of $1.26 and the year-ago loss of $1.20. Full year revenues came in at $668.8 million, down 11.8%. Despite a decline in revenues, Amylin posted better-than-expected results due to lower expenses. We believe the company will continue controlling costs and have reduced our 2011 loss estimate by 22 cents. Meanwhile, Amylin faced a huge setback in 2010 when it failed to gain approval for its lead pipeline candidate, Bydureon, for the second time. Amylin and its partners, Eli Lilly and Company (LLY) and Alkermes, Inc. (ALKS), were looking to get Bydureon approved for the treatment of type II diabetes. On the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/29/amln-amylin-pharmaceuticals-analyst-reports-neutral-on-shares/68498/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PLX) Protalix BioTherapeutics Sees FDA Setback for Gaucher Drug</title>
		<link>http://www.stockbloghub.com/2011/03/04/plx-protalix-biotherapeutics-sees-fda-setback-for-gaucher-drug/67728</link>
		<comments>http://www.stockbloghub.com/2011/03/04/plx-protalix-biotherapeutics-sees-fda-setback-for-gaucher-drug/67728#comments</comments>
		<pubDate>Sat, 05 Mar 2011 00:49:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67728</guid>
		<description><![CDATA[Protalix BioTherapeutics, Inc. (PLX) was dealt a huge blow recently with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for the company’s Gaucher disease candidate, taliglucerase alfa. FDA Requests Additional Information The FDA asked the company to provide additional information related to clinical and chemistry, manufacturing and controls (CMC). While the agency did not ask the company to conduct additional studies, it asked Protalix to provide data from the company’s switchover and long-term extension trials. Besides this, the FDA asked the company to submit information on testing specifications and assay validation. Depending on specific requirements, the Gaucher disease candidate&#8217;s approval could get delayed by a year. The first-round approval of taliglucerase alfa would have been a major boost for Protalix, which has a strong marketing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/04/plx-protalix-biotherapeutics-sees-fda-setback-for-gaucher-drug/67728/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NUE) Nucor Provides Guidance &#8211; Analyst Raises Estimates</title>
		<link>http://www.stockbloghub.com/2010/03/18/nue-nucor-provides-guidance-analyst-raises-estimates/31054</link>
		<comments>http://www.stockbloghub.com/2010/03/18/nue-nucor-provides-guidance-analyst-raises-estimates/31054#comments</comments>
		<pubDate>Thu, 18 Mar 2010 18:28:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Steel & Iron]]></category>
		<category><![CDATA[Arcelor Mittal]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[MT]]></category>
		<category><![CDATA[Nucor Corporation]]></category>
		<category><![CDATA[NUE]]></category>
		<category><![CDATA[United States Steel Corporation]]></category>
		<category><![CDATA[X]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31054</guid>
		<description><![CDATA[Nucor Corporation (NUE) provided its first quarter 2010 earnings update, indicating it expected earnings per share to be in the range of a loss of 5 cents to earnings of 5 cents per share. The Zacks Consensus Estimate is pegged at net earnings of 2 cents in the first quarter. Nucor had reported a loss of 60 cents in the first quarter of 2008. Nucor’s guidance is driven by higher expected operating rates at its beam and bar mills. The company is anticipating operating rates of 55% and 63% at its beam and bar mills, respectively, in the first quarter, up from 11% and 10% in the previous quarter. Nucor also foresees 85% and 90% utilization at its sheet and plate mills, up 22% each from prior quarter levels. With ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/18/nue-nucor-provides-guidance-analyst-raises-estimates/31054/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GGB) Gerdau S.A. Margins Recovered</title>
		<link>http://www.stockbloghub.com/2009/11/07/ggb-gerdau-s-a-margins-recovered/19826</link>
		<comments>http://www.stockbloghub.com/2009/11/07/ggb-gerdau-s-a-margins-recovered/19826#comments</comments>
		<pubDate>Sun, 08 Nov 2009 00:37:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Steel & Iron]]></category>
		<category><![CDATA[CLF]]></category>
		<category><![CDATA[Cliffs Natural Resources Inc.]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[Gerdau S.A.]]></category>
		<category><![CDATA[GGB]]></category>
		<category><![CDATA[Steel Dynamics Inc.]]></category>
		<category><![CDATA[STLD]]></category>
		<category><![CDATA[United States Steel Corporation]]></category>
		<category><![CDATA[VALE]]></category>
		<category><![CDATA[Vale S.a.]]></category>
		<category><![CDATA[X]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19826</guid>
		<description><![CDATA[Today, Gerdau S.A. (GGB) announced consolidated results for the third quarter of 2009. The company did not provide comparable year-on-year figures in a securities filing. Sales reached 3.9 million tons in the quarter, 15% higher than in the second quarter of 2009, reflecting the recovery in the main sectors that consume the company&#8217;s products. Net Revenue reached R$6.8 billion in the 3rd quarter of 2009, 6% higher than in the previous quarter. Third quarter EBITDA reached R$1.4 billion, more than double the amount in the 2nd quarter of 2009. The EBITDA margin increased to 20.2% in the 3rd quarter of 2009 from 9.3% in the 2nd quarter. Net Income was R$655 million in the quarter, compared to a net loss of R$329 million in the previous quarter, reflecting the recovery ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/07/ggb-gerdau-s-a-margins-recovered/19826/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

